Warm Autoimmune Hemolytic Anemia (wAIHA)

Immunology
3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 2 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Sanofi
SanofiPARIS, France
2 programs
2
Isatuximab SAR650984Phase 21 trial
rilzabrutinibPhase 2Small Molecule1 trial
Active Trials
NCT04661033Terminated8Est. Jun 2023
NCT05002777Active Not Recruiting22Est. Dec 2029
Annexon Biosciences
Annexon BiosciencesCA - Brisbane
1 program
1
ANX005Phase 21 trial
Active Trials
NCT04691570CompletedEst. Jan 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Sanofirilzabrutinib
Annexon BiosciencesANX005
SanofiIsatuximab SAR650984

Clinical Trials (3)

Total enrollment: 30 patients across 3 trials

NCT05002777Sanofirilzabrutinib

Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)

Start: Dec 2021Est. completion: Dec 202922 patients
Phase 2Active Not Recruiting

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)

Start: Nov 2021Est. completion: Jan 2023
Phase 2Completed
NCT04661033SanofiIsatuximab SAR650984

Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)

Start: Sep 2021Est. completion: Jun 20238 patients
Phase 2Terminated

Related Jobs in Immunology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space